CD44 and lymphoma: Overall these in vivo data indicate that abolishing the IN–BET interaction via a single point mutation in MLV IN can significantly alter the integration pattern by retargeting MLV integration away from enhancers, but it cannot suppress the development of lymphomas due to insertional mutagenesis [55].